

acromegaly

Drugs

SIGNIFOR, SIGNIFOR LAR, SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 120 MG/0.5 ML, 60 MG/0.2 ML, 90 MG/0.3 ML, SOMAVERT

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide clinical documentation of Acromegaly diagnosis

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

antineoplastics

Drugs

ABRAXANE, AFINITOR, AFINITOR DISPERZ, ALIMTA INTRAVENOUS RECON SOLN 500 MG, AVASTIN, *azacitidine*, BICNU, *bleomycin injection recon soln 30 unit*, BOSULIF ORAL TABLET 100 MG, 500 MG, BUSULFEX, CAPRELSA ORAL TABLET 100 MG, 300 MG, *carboplatin intravenous solution*, *cisplatin*, *cladribine*, CLOLAR, COMETRIQ, *cyclophosphamide oral capsule*, *cytarabine*, *cytarabine (pf) injection solution 2 gram/20 ml (100 mg/ml)*, *dacarbazine intravenous recon soln 200 mg*, *decitabine*, *docetaxel intravenous solution 80 mg/4 ml (20 mg/ml)*, *80 mg/8 ml (10 mg/ml)*, *doxorubicin intravenous solution 50 mg/25 ml*, ELIGARD, ELIGARD (3 MONTH), ELIGARD (4 MONTH), ELIGARD (6 MONTH), EMCYT, ERIVEDGE, ERWINAZE, FARESTON, FASLODEX, FIRMAGON KIT W DILUENT SYRINGE, *fludarabine intravenous recon soln*, FOLOTYN INTRAVENOUS SOLUTION 40 MG/2 ML (20 MG/ML), *gemcitabine intravenous recon soln 1 gram*, GILOTRIF, GLEEVEC, HALAVEN, HEXALEN, ICLUSIG ORAL TABLET 45 MG, *idarubicin*, *ifosfamide intravenous recon soln 1 gram*, IMBRUVICA, INLYTA ORAL TABLET 1 MG, 5 MG, INTRON A INJECTION RECON SOLN, INTRON A INJECTION SOLUTION 6 MILLION UNIT/ML, *irinotecan intravenous solution 100 mg/5 ml*, ISTODAX, JAKAFI, JEVTANA, KADCYLA INTRAVENOUS RECON SOLN 100 MG, LUPRON DEPOT, LUPRON DEPOT (3 MONTH), LUPRON DEPOT (4 MONTH), LUPRON DEPOT (6 MONTH), LUPRON DEPOT-PED INTRAMUSCULAR KIT 15 MG, MATULANE, MEKINIST ORAL TABLET 0.5 MG, 2 MG, *melphalan hcl*, *mitoxantrone*, MUSTARGEN, NEXAVAR, *oxaliplatin intravenous solution 100 mg/20 ml*, *paclitaxel*, PANRETIN, POMALYST, PROLEUKIN, REVLIMID ORAL CAPSULE 10 MG, 15 MG, 2.5 MG, 25 MG, 5 MG, RITUXAN, SOLTAMOX, SPRYCEL, STIVARGA, SUTENT, SYNRIPO, TABLOID, TAFINLAR, TARCEVA ORAL TABLET 100 MG, 150 MG, 25 MG, TARGRETIN, TASIGNA, *topotecan intravenous recon soln*, TORISEL, TREANDA INTRAVENOUS RECON SOLN 100 MG, TRELSTAR INTRAMUSCULAR SYRINGE 11.25 MG/2 ML, 3.75 MG/2 ML, TRISENOX, TYKERB, VELCADE, *vinblastine intravenous solution*, VINCASAR PFS INTRAVENOUS SOLUTION 1 MG/ML, *vincristine intravenous solution 1 mg/ml*, *vinorelbine intravenous solution 50 mg/5 ml*, VOTRIENT, XALKORI ORAL CAPSULE 200 MG, XTANDI, YERVOY INTRAVENOUS SOLUTION 50 MG/10 ML (5 MG/ML), ZALTRAP INTRAVENOUS SOLUTION 100 MG/4 ML (25 MG/ML), ZANOSAR, ZELBORAF, ZOLINZA, ZORTRESS

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

N/A

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

asthma therapy

Drugs

XOLAIR

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

For use of asthma therapy: Must have documented diagnosis of asthma and must provide all pulmonary function tests from within the previous 3 months. For use of chronic idiopathic urticaria: Must have documented diagnosis of chronic idiopathic urticaria and must provide trial and failure of antihistamine treatment.

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by a pulmonologist, an allergist, a dermatologist or an immunologist.

Coverage Duration

1 year

Other Criteria

N/A

bone marrow transplant

Drugs

MOZOBIL

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide clinical documentation of proper diagnosis.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

cardiovascular therapy agents pulmonary arterial hypertensive agents

Drugs

ADCIRCA, ADEMPAS, LETAIRIS, OPSUMIT, *sildenafil oral*, TRACLEER

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must have documentation of Pulmonary Arterial Hypertension Group 1

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by a Cardiologist or Pulmonologist.

Coverage Duration

1 year

Other Criteria

N/A

carimune

Drugs

CARIMUNE NF NANOFILTERED INTRAVENOUS RECON SOLN 6 GRAM

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide current progress notes.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

Drugs

CINRYZE

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

1. Patient is diagnosed with idiopathic angioedema or drug induced angioedema.

Required Medical Information

Must provide clinical documentation detailing diagnosis, treatment history and disease history. Verify medication is being used for prophylaxis of HAE attacks

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by or in consultation with an allergist, immunologist or hematologist.

Coverage Duration

1 year

Other Criteria

N/A

Drugs

cidofovir, ganciclovir sodium

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Documentation of CMV Diagnosis.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

copd therapy

Drugs

DALIRESP

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must have documented diagnosis of COPD.

Age Restriction

N/A

Prescriber Restriction

Must have be prescribed by a pulmonologist.

Coverage Duration

1 year

Other Criteria

N/A

daklinza

Drugs

DAKLINZA ORAL TABLET 30 MG, 60 MG

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Criteria will be applied consistent with current AASLD-IDSA guidance.

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by a gastroenterologist, Infectious Disease specialist or Hepatologist.

Coverage Duration

1 year

Other Criteria

N/A

desmopressin

Drugs

desmopressin injection

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Diagnosis of Hemophilia A with Factor VIII coagulant level greater than 5% or Von Willebrands Disease Type 1

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

exjade

Drugs

EXJADE, FERRIPROX ORAL TABLET

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Documentation of trial and failure of Desferal.

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by Hematologist.

Coverage Duration

1 year

Other Criteria

N/A

Drugs

CARBAGLU, CYSTAGON, ESBRIET ORAL CAPSULE, FARYDAK, HETLIOZ, JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 5 MG, KYNAMRO, LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1/DAY), 20 MG/DAY (10 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1), NORTHERA, NOVAREL INTRAMUSCULAR RECON SOLN 10,000 UNIT, PREGNYL, RAVICTI, SIRTURO, VPRIV

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

N/A

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

fentanyl

Drugs

fentanyl citrate, LAZANDA NASAL SPRAY, NON-AEROSOL 100 MCG/SPRAY, 400 MCG/SPRAY

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide clinical documentation detailing diagnosis of Cancer and trial/failure of Fentanyl patches.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

Drugs

FIRAZYR

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

1. Medication is being used for prophylaxis of HAE attacks. 2. Patient is diagnosed with idiopathic angioedema or drug induced angioedema.

Required Medical Information

Must provide clinical documentation detailing diagnosis, treatment history and disease history.

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by or in consultation with an allergist, immunologist or hematologist.

Coverage Duration

1 year

Other Criteria

N/A

Drugs

FORTEO

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

Cannot be used for longer than 2 years

Required Medical Information

Must provide clinical documentation detailing the diagnosis and treatment history, documented trial and failure or intolerance to oral biphosphonates and injectable biphosphonates (including date range of therapy), BMD results confirming T-score of -2.5 or less.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

growth deficiency

Drugs

INCRELEX, NORDITROPIN FLEXPRO, NUTROPIN AQ NUSPIN SUBCUTANEOUS PEN INJECTOR 10 MG/2 ML (5 MG/ML), 5 MG/2 ML (2.5 MG/ML)

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide clinical documentation of Primary Growth Deficiency diagnosis

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

Drugs

HARVONI

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

1. Autoimmune hepatitis 2. Request is for greater than 24 weeks of therapy

Required Medical Information

Documented diagnosis of Genotype 1a, 1b, 4, 5, or 6 infection, lab report documenting viral load, detailed medical history of previous treatment.

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by a gastroenterologist, hepatologist, or infectious disease specialist

Coverage Duration

1 year

Other Criteria

N/A

hepatitis c

Drugs

PEGASYS SUBCUTANEOUS SOLUTION, REBETOL ORAL SOLUTION, RIBASPHERE ORAL TABLET 400 MG, 600 MG, *ribavirin oral capsule*, *ribavirin oral tablet 200 mg*

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Documentation of Hepatitis C. Documentation of appropriate genotype.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

Drugs

INVEGA SUSTENNA, INVEGA TRINZA

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

1. Member is not receiving concomitant treatment with Carbamazepine. 2. Members over 65 with dementia and psychosis.

Required Medical Information

Must provide clinical documentation detailing diagnosis and treatment history, documented trial and failure of Risperdal and Zyprexa or Geodon.

Age Restriction

Must be 18 years or older.

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

iv antibiotics

Drugs

CUBICIN, DORIBAX INTRAVENOUS RECON SOLN 500 MG, *imipenem-cilastatin*, *piperacillin-tazobactam intravenous recon soln 3.375 gram, 4.5 gram*

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Current Culture and Sensitivity to support the use of the requested antibiotic and excludes use of non restricted antibiotics. Documentation of failure or rationale documenting why non-restricted antibiotics cannot be used. Must add current progress notes.

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by an Infectious Disease Specialist.

Coverage Duration

1 year

Other Criteria

N/A

iv antifungal

Drugs

ABELCET, AMBISOME, CANCIDAS, *fluconazole in nacl (iso-osm) intravenous piggyback 400 mg/200 ml*, *voriconazole intravenous*

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Current Culture and Sensitivity to support the use of the antifungal medication. Documentation of failure or rationale documenting why non-restricted antifungals cannot be used. Must add current progress notes.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

Drugs

JUXTAPID ORAL CAPSULE 30 MG, 40 MG, 60 MG

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

N/A

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by hematologist, oncologist, cardiologist, endocrinologist or nephrologist.

Coverage Duration

1 year

Other Criteria

N/A

Drugs

KINERET

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

For use of Rheumatoid Arthritis: Must have documented diagnosis of Rheumatoid Arthritis and must provide documentation of failed intolerance to Methotrexate and Humira. For use of Cryopyrin-Associated Periodic Syndromes (CAPS): Must have documented diagnosis of Cryopyrin-Associated Periodic Syndromes (CAPS).

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

Drugs

KORLYM

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

1. Member has type 2 diabetes mellitus unrelated to Endogenous Cushing's Syndrome. 2. Member is diagnosed with exogenous or iatrogenic Cushing's syndrome. 3. Drug is being used to treat psychotic features of psychotic depression. 4. Drug is being used primarily for hypertension.

Required Medical Information

N/A

Age Restriction

Must be 18 years or older.

Prescriber Restriction

Must be prescribed by or in consultation with an endocrinologist.

Coverage Duration

1 year

Other Criteria

N/A

kuvan

Drugs

KUVAN ORAL TABLET,SOLUBLE

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must have documentation of PKU

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

leukine

Drugs

LEUKINE INJECTION RECON SOLN

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

N/A

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

leuprolide

Drugs

leuprolide subcutaneous kit

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide current progress notes.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

lidoderm

Drugs

lidocaine topical adhesive patch,medicated

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide clinical documentation of diagnosis of postherpetic neuralgia.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

lumizyme

Drugs

LUMIZYME

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Confirmed diagnosis of Pompe's disease.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

lung enzyme therapy

Drugs

PROLASTIN-C, ZEMAIRA

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Clinically documented alpha-1 antitrypsin deficiency. Clinical evidence of emphysema. PiZZ, PiZ() or Pi(,) phenotype (homozygous) alpha 1-antitrypsin deficiency or other phenotypes associated with serum alpha 1-antitrypsin concentrations less than 80 mg/dl. Serum alpha 1-antitrypsin (ATT) greater than 80mg/dl (35% of normal). Progressive panacinar emphysema with documented rate of decline in FEV1.

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by a pulmonologist.

Coverage Duration

1 year

Other Criteria

N/A

lupus

Drugs

BENLYSTA INTRAVENOUS RECON SOLN 120 MG

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Documentation of diagnosis.

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by a rheumatologist.

Coverage Duration

1 year

Other Criteria

N/A

Drugs

MULTAQ

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

Patients with NYHA Class IV heart failure or NYHA Class II - III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic. Second- or third- degree atrioventricular (AV) block or sick sinus syndrome

Required Medical Information

Must provide clinical documentation of proper diagnosis.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

narcolepsy

Drugs

modafinil

Covered Uses

All medically accepted indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide clinical documentation detailing the diagnosis of Narcolepsy, Shift Work Sleep Disorder, or obstructive sleep apnea. If for Narcolepsy, must show trial and failure to at least one formulary/preferred agent, such as Methylphenidate or dextroamphetamine, or rationale as to why these agents cannot be used. Must provide clinical documentation indicating the use to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea.

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by a Sleep specialist, Neurologist or Pulmonary specialist.

Coverage Duration

1 year

Other Criteria

N/A

neutropenic

Drugs

NEULASTA SUBCUTANEOUS SYRINGE, NEUPOGEN INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6 ML, NEUPOGEN INJECTION SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Labs must be submitted that support the diagnosis of neutropenia.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

Drugs

NUEDEXTA

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Documented diagnosis of pseudobulbar affect (PBA).

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

Drugs

NULOJIX

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide clinical documentation of a new kidney transplant, patient must be Epstein-Barr virus seropositive

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by a physician experienced in immunosuppressive therapy and management of kidney transplant patients

Coverage Duration

1 year

Other Criteria

N/A

octreotide

Drugs

octreotide acetate injection solution 1,000 mcg/ml

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide current progress notes.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

oral antibiotics

Drugs

linezolid oral suspension for reconstitution, linezolid oral tablet, ZYVOX ORAL SUSPENSION FOR RECONSTITUTION

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Current Culture and Sensitivity to support the use of the requested antibiotic and excludes use of non restricted antibiotics. Documentation of failure or rationale documenting why non-restricted oral antibiotics cannot be used. Must add current progress notes

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by an Infectious Disease Specialist.

Coverage Duration

1 year

Other Criteria

N/A

osteoporosis

Drugs

PROLIA, XGEVA, *zoledronic acid intravenous solution, zoledronic acid-mannitol-water*

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must have labs and bone density scan submitted to establish proper diagnosis.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

Drugs

REPATHA SURECLICK, REPATHA SYRINGE

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Repatha: Must provide clinical documentation of primary heterozygous familial hypercholesterolemia in combination with a statin or primary hypercholesterolemia in combination with a statin or homozygous familial hypercholesterolemia, or provide clinical documentation indicating a contraindication or intolerance to statin therapy.

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by a Gastroenterologist, Infectious Disease specialist, Cardiologist, Endocrinologist or Hepatologist.

Coverage Duration

1 year

Other Criteria

N/A

photochemotherapy

Drugs

methoxsalen, OXSORALEN ULTRA

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

N/A

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

Drugs

PICATO

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide clinical documentation detailing the diagnosis and treatment history, documented trial and failure of Fluorouracil or Imiquimod.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

promacta

Drugs

PROMACTA

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide current progress notes.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

Drugs

RANEXA

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Diagnosis of angina with documentation of failure of nitroglycerin.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

risperdal

Drugs

RISPERDAL CONSTA, RISPERDAL M-TAB

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide clinical documentation detailing the diagnosis and treatment history, documented trial and failure or inability to use oral antipsychotic agents.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

sabril

Drugs

SABRIL

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide clinical documentation of refractory complex partial seizures or infantile spasms, documented trial and failure of 2 other anticonvulsant agents, baseline eye exam.

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by a specialist in the neurology field of study.

Coverage Duration

1 year

Other Criteria

N/A

sovaldi

Drugs

SOVALDI

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

1. Autoimmune hepatitis.

Required Medical Information

Criteria will be applied consistent with current AASLD-IDSA guidance.

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by a gastroenterologist, Infectious Disease specialist or Hepatologist.

Coverage Duration

1 year

Other Criteria

N/A

symlin

Drugs

SYMLINPEN 120, SYMLINPEN 60

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Diagnosis of Type II diabetes HbA1c greater than 7%. Failure to reach HbA1c goal with maximum dose of metformin (1,500mg/day) or TZD (pioglitazone at 45mg/day, rosiglitazone at 8mg/day), for at least 90 days over the past 120 days or Diagnosis of Type I diabetes who have failed to achieve desired glucose control despite optimal insulin therapy, or intolerance to the aforementioned therapies.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

Drugs

SYNAGIS INTRAMUSCULAR SOLUTION 50 MG/0.5 ML

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

1. Patient has hemodynamically insignificant heart disease (eg. Secundum atrialseptal defect, small ventricular septal defect, pullmonic stenosis, uncomplicatedaortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus). Must provide clinical documentation of proper diagnosis.

Required Medical Information

N/A

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

technivie

Drugs

TECHNIVIE

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Criteria will be applied consistent with current AASLD-IDSA guidance.

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by a gastroenterologist, Infectious Disease specialist or Hepatologist.

Coverage Duration

1 year

Other Criteria

N/A

thalomid

Drugs

THALOMID

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide clinical documentation of proper diagnosis.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

Drugs

ENBREL, ENBREL SURECLICK, HUMIRA, HUMIRA PEDIATRIC CROHN'S START SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML, HUMIRA PEN, HUMIRA PEN CROHN'S-UC-HS START, HUMIRA PEN PSORIASIS-UVEITIS, ORENCIA (WITH MALTOSE), ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, REMICADE, SIMPONI SUBCUTANEOUS SYRINGE

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide clinical documentation of proper diagnosis.

Age Restriction

N/A

Prescriber Restriction

Must be prescribed by a dermatologist, ophthalmologist, gastroenterologist or rheumatologist.

Coverage Duration

1 year

Other Criteria

N/A

Drugs

tobramycin in 0.225 % nacl

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide clinical documentation of Cystic Fibrosis diagnosis

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

xenazine

Drugs

XENAZINE

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide clinical documentation of Huntingtons Disease diagnosis

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

zytiga

Drugs

ZYTIGA ORAL TABLET 250 MG

Covered Uses

All FDA-approved indications not otherwise excluded from Part D

Exclusion Criteria

N/A

Required Medical Information

Must provide clinical documentation of proper diagnosis.

Age Restriction

N/A

Prescriber Restriction

N/A

Coverage Duration

1 year

Other Criteria

N/A

Index of Drugs

ABELCET.....	22	<i>docetaxel intravenous solution 80 mg/4 ml (20 mg/ml), 80 mg/8 ml (10 mg/ml)</i>	2	HUMIRA PEN.....	53
ABRAXANE.....	2	DORIBAX INTRAVENOUS RECON SOLN 500 MG.....	21	HUMIRA PEN CROHN'S-UC-HS START.....	53
ADCIRCA.....	5	<i>doxorubicin intravenous solution 50 mg/25 ml</i>	2	HUMIRA PEN PSORIASIS-UVEITIS.....	53
ADEMPAS.....	5	ELIGARD.....	2	ICLUSIG ORAL TABLET 45 MG.....	2
AFINITOR.....	2	ELIGARD (3 MONTH).....	2	<i>idarubicin</i>	2
AFINITOR DISPERZ.....	2	ELIGARD (4 MONTH).....	2	<i>ifosfamide intravenous recon soln 1 gram</i>	2
ALIMTA INTRAVENOUS RECON SOLN 500 MG.....	2	ELIGARD (6 MONTH).....	2	IMBRUVICA.....	2
AMBISOME.....	22	EMCYT.....	2	<i>imipenem-cilastatin</i>	21
AVASTIN.....	2	ENBREL.....	53	INCRELEX.....	17
<i>azacitidine</i>	2	ENBREL SURECLICK.....	53	INLYTA ORAL TABLET 1 MG, 5 MG.....	2
BENLYSTA INTRAVENOUS RECON SOLN 120 MG.....	32	ERIVEDGE.....	2	INTRON A INJECTION RECON SOLN.....	2
BICNU.....	2	ERWINAZE.....	2	INTRON A INJECTION SOLUTION 6 MILLION UNIT/ML.....	2
<i>bleomycin injection recon soln 30 unit</i>	2	ESBRIET ORAL CAPSULE..	13	INVEGA SUSTENNA.....	20
BOSULIF ORAL TABLET 100 MG, 500 MG.....	2	EXJADE.....	12	INVEGA TRINZA.....	20
BUSULFEX.....	2	FARESTON.....	2	<i>irinotecan intravenous solution 100 mg/5 ml</i>	2
CANCIDAS.....	22	FARYDAK.....	13	ISTODAX.....	2
CAPRELSA ORAL TABLET 100 MG, 300 MG.....	2	FASLODEX.....	2	JAKAFI.....	2
CARBAGLU.....	13	<i>fentanyl citrate</i>	14	JEVTANA.....	2
<i>carboplatin intravenous solution</i>	2	FERRIPROX ORAL TABLET	12	JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 5 MG.....	13
CARIMUNE NF NANOFILTERED INTRAVENOUS RECON SOLN 6 GRAM.....	6	FIRAZYR.....	15	JUXTAPID ORAL CAPSULE 30 MG, 40 MG, 60 MG.....	23
<i>cidofovir</i>	8	FIRMAGON KIT W DILUENT SYRINGE.....	2	KADCYLA INTRAVENOUS RECON SOLN 100 MG.....	2
CINRYZE.....	7	<i>fluconazole in nacl (iso-osm) intravenous piggyback 400 mg/200 ml</i>	22	KINERET.....	24
<i>cisplatin</i>	2	<i>fludarabine intravenous recon soln</i>	2	KORLYM.....	25
<i>cladribine</i>	2	FOLOTYN INTRAVENOUS SOLUTION 40 MG/2 ML (20 MG/ML).....	2	KUVAN ORAL TABLET,SOLUBLE.....	26
CLOLAR.....	2	FORTEO.....	16	KYNAMRO.....	13
COMETRIQ.....	2	<i>ganciclovir sodium</i>	8	LAZANDA NASAL SPRAY, NON-AEROSOL 100 MCG/SPRAY, 400 MCG/SPRAY.....	14
CUBICIN.....	21	<i>gemcitabine intravenous recon soln 1 gram</i>	2	LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1/DAY), 20 MG/DAY (10 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1).....	13
<i>cyclophosphamide oral capsule</i>	2	GILOTRIF.....	2	LETAIRIS.....	5
CYSTAGON.....	13	GLEEVEC.....	2	LEUKINE INJECTION RECON SOLN.....	27
<i>cytarabine</i>	2	HALAVEN.....	2		
<i>cytarabine (pf) injection solution 2 gram/20 ml (100 mg/ml)</i>	2	HARVONI.....	18		
<i>dacarbazine intravenous recon soln 200 mg</i>	2	HETLIOZ.....	13		
DAKLINZA ORAL TABLET 30 MG, 60 MG.....	10	HEXALEN.....	2		
DALIRESP.....	9	HUMIRA.....	53		
<i>decitabine</i>	2	HUMIRA PEDIATRIC CROHN'S START SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML	53		
<i>desmopressin injection</i>	11				

<i>leuprolide subcutaneous kit</i> ... 28	ORENCIA (WITH MALTOSE)..... 53	SOMAVERT..... 1
<i>lidocaine topical adhesive patch, medicated</i> 29	ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML..... 53	SOVALDI..... 48
<i>linezolid oral suspension for reconstitution</i> 39	<i>oxaliplatin intravenous solution 100 mg/20 ml</i> 2	SPRYCEL..... 2
<i>linezolid oral tablet</i> 39	OXSORALEN ULTRA..... 42	STIVARGA..... 2
LUMIZYME..... 30	<i>paclitaxel</i> 2	SUTENT..... 2
LUPRON DEPOT..... 2	PANRETIN..... 2	SYMLINPEN 120..... 49
LUPRON DEPOT (3 MONTH)..... 2	PEGASYS SUBCUTANEOUS SOLUTION..... 19	SYMLINPEN 60..... 49
LUPRON DEPOT (4 MONTH)..... 2	PICATO..... 43	SYNAGIS INTRAMUSCULAR SOLUTION 50 MG/0.5 ML.... 50
LUPRON DEPOT (6 MONTH)..... 2	<i>piperacillin-tazobactam intravenous recon soln 3.375 gram, 4.5 gram</i> 21	SYNRIBO..... 2
LUPRON DEPOT-PED INTRAMUSCULAR KIT 15 MG..... 2	POMALYST..... 2	TABLOID..... 2
MATULANE..... 2	PREGNYL..... 13	TAFINLAR..... 2
MEKINIST ORAL TABLET 0.5 MG, 2 MG..... 2	PROLASTIN-C..... 31	TARCEVA ORAL TABLET 100 MG, 150 MG, 25 MG..... 2
<i>melphalan hcl</i> 2	PROLEUKIN..... 2	TARGRETIN..... 2
<i>methoxsalen</i> 42	PROLIA..... 40	TASIGNA..... 2
<i>mitoxantrone</i> 2	PROMACTA..... 44	TECHNIVIE..... 51
<i>modafinil</i> 34	RANEXA..... 45	THALOMID..... 52
MOZOBIL..... 4	RAVICTI..... 13	<i>tobramycin in 0.225 % nacl</i> ... 54
MULTAQ..... 33	REBETOL ORAL SOLUTION..... 19	<i>topotecan intravenous recon soln</i> 2
MUSTARGEN..... 2	REMICADE..... 53	TORISEL..... 2
NEULASTA SUBCUTANEOUS SYRINGE..... 35	REPATHA SURECLICK..... 41	TRACLEER..... 5
NEUPOGEN INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6 ML..... 35	REPATHA SYRINGE..... 41	TREANDA INTRAVENOUS RECON SOLN 100 MG..... 2
NEUPOGEN INJECTION SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML..... 35	REVLIMID ORAL CAPSULE 10 MG, 15 MG, 2.5 MG, 25 MG, 5 MG..... 2	TRELSTAR INTRAMUSCULAR SYRINGE 11.25 MG/2 ML, 3.75 MG/2 ML..... 2
NEXAVAR..... 2	RIBASPHERE ORAL TABLET 400 MG, 600 MG.... 19	TRISENOX..... 2
NORDITROPIN FLEXPRO... 17	<i>ribavirin oral capsule</i> 19	TYKERB..... 2
NORTHERA..... 13	<i>ribavirin oral tablet 200 mg</i> 19	VELCADE..... 2
NOVAREL INTRAMUSCULAR RECON SOLN 10,000 UNIT..... 13	RISPERDAL CONSTA..... 46	<i>vinblastine intravenous solution</i> 2
NUDEXTA..... 36	RISPERDAL M-TAB..... 46	VINCASAR PFS INTRAVENOUS SOLUTION 1 MG/ML..... 2
NULOJIX..... 37	RITUXAN..... 2	<i>vincristine intravenous solution 1 mg/ml</i> 2
NUTROPIN AQ NUSPIN SUBCUTANEOUS PEN INJECTOR 10 MG/2 ML (5 MG/ML), 5 MG/2 ML (2.5 MG/ML)..... 17	SABRIL..... 47	<i>vinorelbine intravenous solution 50 mg/5 ml</i> 2
<i>octreotide acetate injection solution 1,000 mcg/ml</i> 38	SIGNIFOR..... 1	<i>voriconazole intravenous</i> 22
OPSUMIT..... 5	SIGNIFOR LAR..... 1	VOTRIENT..... 2
	<i>sildenafil oral</i> 5	VPRIV..... 13
	SIMPONI SUBCUTANEOUS SYRINGE..... 53	XALKORI ORAL CAPSULE 200 MG..... 2
	SIRTURO..... 13	XENAZINE..... 55
	SOLTAMOX..... 2	XGEVA..... 40
	SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 120 MG/0.5 ML, 60 MG/0.2 ML, 90 MG/0.3 ML..... 1	XOLAIR..... 3
		XTANDI..... 2

YERVOY INTRAVENOUS SOLUTION 50 MG/10 ML (5 MG/ML).....	2
ZALTRAP INTRAVENOUS SOLUTION 100 MG/4 ML (25 MG/ML).....	2
ZANOSAR.....	2
ZELBORAF.....	2
ZEMAIRA.....	31
<i>zoledronic acid intravenous solution</i>	40
<i>zoledronic acid-mannitol- water</i>	40
ZOLINZA.....	2
ZORTRESS.....	2
ZYTIGA ORAL TABLET 250 MG.....	56
ZYVOX ORAL SUSPENSION FOR RECONSTITUTION.....	39